Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus
-
Upload
vall-dhebron-institute-of-research-vhir -
Category
Health & Medicine
-
view
675 -
download
3
description
Transcript of Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus
![Page 1: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/1.jpg)
«Allogenicity & Immunogenicity of Stem Cell Therapy : a Cardiovascular Focus »
DOMINIQUE CHARRON,MD,PhD
Dominique.Charron @ sls.aphp.frLaboratoire « Jean Dausset » & INSERM U 940
Hopital Saint-Louis ,IUH ,Université Paris-Diderot , France
VHIR CONFERENCE 2013BARCELONA
![Page 2: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/2.jpg)
XXth Century
HLA, MHC ,Cytokines,Receptors….
…TRANSPLANTATION, AUTOIMMUNITY,INFECTIONS
XXth Century
HLA, MHC ,Cytokines,Receptors….
…TRANSPLANTATION, AUTOIMMUNITY,INFECTIONS
IMMUNOGENETICS & MEDICINE
XXI st Century
HLA & MEDICINE (Schizophrenia,Parkinson … )IMMUNO PHARMACOGENETICS (Abacavir,Carbamazepin ,Allopurinol…)REGENERATIVE MEDICINE/CELL & IMMUNO THERAPIES
TOWARD « SYSTEMS BIOLOGY/SYSTEMS MEDICINE »
.
![Page 3: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/3.jpg)
Complete sequence and gene map
MHC / HLA
HLA CONSORTIUM – Nature 11/1999
![Page 4: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/4.jpg)
# HLA Alleles
![Page 5: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/5.jpg)
HLA DIVERSITY = BIOLOGICAL SELFHLA DIVERSITY = BIOLOGICAL SELF
2013 : 8496 ALLELES
WE ARE THE LIMIT
![Page 6: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/6.jpg)
TcCytotoxic T-cell
ThHelper T-cell
Allogeneic (Donor) APC(stimulator)
Class I Class II
Allo MHC moleculesfrom the Donor are
recognized by Host T-cells
Pathways of AllorecognitionPathways of Allorecognition
Direct allorecognitionDirect allorecognition
Allogeneic (Donor) Cell
MHC or other moleculesare shed
taken up andprocessed by host APC
Host APC(recipient)
ThHelper T-cell
TcCytotoxic T-cell
Peptide derived from allo moleculespresented on host MHC
to Host T-cellsIndirect allorecognitionIndirect allorecognition
Immune CellImmune Cell
Stem CellStem Cell
![Page 7: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/7.jpg)
Allo Recognition/Activation Pathways
Direct Direct vsvs Indirect Indirect
Recognition phase
APC
HLA-peptide
T cell frequency
Donor Recipient
Donor -Donor Recipient - Donor
Pre-existing1/103 – 1/104 1/105 – 1/106
Immediate ResponseEffector phase
Cytokine production(inflammatory response)
B cell activation(Ab production)
+
+++
++
-Direct cytotoxicity(of donor tissue) -++
Th
Tc
Duration of responseShort lived(donor APC)
long lived(donor peptide)
Outcome Acute Rejection Chronic Rejection
![Page 8: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/8.jpg)
CONSEQUENCES OF HLA HISTO- INCOMPATIBILITY IN TRANSPLANTATION ……2012
T CELL MEDIATED : REJECTION (ORGANS) & GVH(HSCT)
ANTI HLA ANTIBODY MEDIATED: CHRONIC REJECTION(ORGANS) & NO ENGRAFTMENT (HSCT)
2013 CHANGE OF PARADIGM
![Page 9: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/9.jpg)
![Page 10: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/10.jpg)
Antibody-mediated vascular rejection of kidney allografts:a population-based study
Carmen Lefaucheur*, Alexandre Loupy*, Dewi Vernerey, Jean-Paul Duong-Van-Huyen, Caroline Suberbielle, Dany Anglicheau, Jérôme Vérine, Thibaut Beuscart, Dominique Nochy, Patrick Bruneval, Dominique Charron, Michel Delahousse, Jean-Philippe Empana, Gary S Hill, Denis Glotz, Christophe Legendre, Xavier Jouven
LANCET Nov 23,2012
![Page 11: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/11.jpg)
Population based study2079 patients(nck/sls)+ 602validation samples(foch)
302 biopsy proven rejection(1998-2008)
CINICAL, HISTO PATHOLOGICAL(including C4d)& IMMUNOLOGICAL(DSA) DATA
Hierarchical cluster analysisunsupervised principal component
4 patterns of rejectionTCMR/V+ :T cell mediated rejection (26 9 °/°)
ABMR/V+ :Antibody mediated rejection(64 21°/°)
TCMR/V- : T cell mediated rejection without vasculitis(139 46°/°)
ABMR/V- : Antibody mediated rejection without vasculitis(73 24°/°)
![Page 12: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/12.jpg)
PATHOLOGICAL & IMMUNOLOGICAL PHENOTYPES OF THE 4 REJECTION PATTERNS
![Page 13: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/13.jpg)
Endarteritis --
Endarteritis +
Cellular (Tcell) rejection Antibody mediated rejection
TCMR V -
TCMRV+
ABMR V -
ABMR V +
![Page 14: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/14.jpg)
GRAFT SURVIVAL IN THE 4 REJECTION PHENOTYPES
ABMR V+
![Page 15: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/15.jpg)
HLA, MHC AND MUCH MORE….…TRANSPLANTATION, AUTOIMMUNITY AND MUCH MORE
HLA, MHC AND MUCH MORE….…TRANSPLANTATION, AUTOIMMUNITY AND MUCH MORE
HLA in MEDICINEIMMUNOPHARMACOGENETICS REGENERATIVE MEDICINESYSTEMS BIOLOGY
![Page 16: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/16.jpg)
REGENERATIVE MEDICINE AND TRANSPLANTATIONREGENERATIVE MEDICINE AND TRANSPLANTATION
PLURI / MULTIPOTENCY SELF RENEWAL IN VITRO SPECIFIC DIFFERENCIATION IMMUNE PRIVILEGE ?
PLURI / MULTIPOTENCY SELF RENEWAL IN VITRO SPECIFIC DIFFERENCIATION IMMUNE PRIVILEGE ?
BENEFITSBENEFITS
LIMITS OF IN VIVO ENGRAFTMENT AND FUNCTIONALITYLIMITS OF IN VIVO ENGRAFTMENT AND FUNCTIONALITY
IMMUNOGENICITY/ALLOGENICITY/REJECTION/AUTOIMMUNITY ? DISPONIBILITY – TIMELINE AGING SAFETY ETHICAL – REGULATORY ISSUES
IMMUNOGENICITY/ALLOGENICITY/REJECTION/AUTOIMMUNITY ? DISPONIBILITY – TIMELINE AGING SAFETY ETHICAL – REGULATORY ISSUES
![Page 17: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/17.jpg)
THE IMMUNITY FACTORS IN REGENERATIVE CELL THERAPIES
THE IMMUNOGENETIC FACTOR: ALLOGENICITY HLA, MHC and Much More….
THE IMMUNE EFFECTORS: DIRECT vs INDIRECT PATHWAYS OF ALLO RECOGNITION
Cells, Mediators and Allo Antibodies...
THE AGING FACTOR: IMMUNO SENESCENCE
Immune CellImmune Cell
Stem CellStem Cell
Towards an IMMUNOLOGICALLY EDUCATED CHOICE OF SCs
![Page 18: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/18.jpg)
ALLOGENEIC STEM CELLS ARE NOT ALLOGENEIC STEM CELLS ARE NOT IMMUNO PRIVILEGED IMMUNO PRIVILEGED
ALLOGENEIC STEM CELLS ARE NOT ALLOGENEIC STEM CELLS ARE NOT IMMUNO PRIVILEGED IMMUNO PRIVILEGED
MHC EXPRESSION
IMMUNOGENICITY INCREASES UPON DIFFERENCIATION
IN VIVO REJECTION
Immune CellImmune Cell
Stem CellStem Cell
2002 -2008
3 SUPPORTING PAPERS
![Page 19: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/19.jpg)
M. DRUKKER, G. KATZ, A. URBACH, M. SCHULDINER, G. MARKEL, J. ITSKOVITZ-ELDOR, B. REUBINOFF, O. MANDELBOIM, N. BENVENISTY
PNAS, 2002, 99:9864
CHARACTERIZATION OF THE EXPRESSION OF MHC PROTEINS IN HUMAN EMBRYONIC STEM CELLS
2m
HLA-I
HLA-II
721/HLA-G
Fluorescence intensity
Coun
ts
DIFFERENTIATEDUNDIFFERENTIATEDIn vitro In vivo
Immune CellImmune Cell
Stem CellStem Cell
![Page 20: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/20.jpg)
IFN- induction of MHC-I in human ES cells is dose and time dependent
IFN- induction of MHC-I in human ES cells is dose and time dependent
![Page 21: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/21.jpg)
Embryonic Stem Cell Immunogenicity Increases Upon Differentiation After Transplantation Into Ischemic MyocardiumR-J Swijnenburg, M. Tanaka, H. Vogel, J. Baker,T. Kofidis, F. Gunawan, D.R. Lebl, A.D. Caffarelli, J.L. de Bruin, E.V. Fedoseyeva, R.C. Robbins
Circulation. 2005;112:I-166-I-172
Graft infiltration of immune cells after transplantation of in vivo differentiated ESCs
T cells B cells
![Page 22: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/22.jpg)
DIFFERENCIATION OF ALLOGENEIC MESENCHYMAL STEM CELLS INDUCES IMMUNOGENICITY & LIMITS THEIR LONG-TERM BENEFITS FOR MYOCARDIAL REPAIR
Xi-Ping Huang & coll Circulation .2010 ;122:2419-242• Wistar and lewis rats• MSCs untreated vs MSCs cultured with 5-azacytidine(to induce myogenic
differentiation)Flow cytometric & mRNA evaluation of MHC Ia,II and CD86 is increased by
>30% upon differentiation While MHC Ib is decreased -------GFP+ MSCs Implanted into the infarcted myocardium 3 weeks after MI
express low level of MHC Ia when undifferenciated(alpha-SMA-) at day seven & high level of MHC Ia when differenciated(alpha-SMA+) at Day 14(differenciated)
------ Implanted Allogeneic MSCs induce a local immune reaction after 7 days and are not detected in situ after 5 weeks
-------Allogeneic MSCs restore cardiac function as effectively as Syngeneic MSCs for 3 months but not 6 monts after implantation
While immunoprivileged in their undifferenciated state MSCs become immunogenic in vitro & in vivo when differenciated (biphasic immune response)
2O10
![Page 23: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/23.jpg)
ALLOGENICITY/IMMUNOGENICITY &
IMMUNOMODULATORY PROPERTIES of HUMAN
CARDIAC PROGENITOR/STEM CELLS
![Page 24: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/24.jpg)
Human Cardiac Stem/Progenitor Cells Characterization
•Cells from Different donors : Endomyocardic biopsy Collagenase Treatment ckit purification/enrichment • Pluripotency Transcription factors
• CARDIAC LINEAGE SC MARKERS
hCPC Cardiac differenciation potency(in vitro)
CardiomyocytesEndothelial cells
Smooth muscle cells
hCPC Cardiac differenciation potency(in vitro)
CardiomyocytesEndothelial cells
Smooth muscle cells
STEM CELL MARKERS
Nadal-Ginard B et al. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006;3
![Page 25: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/25.jpg)
Immunology of Human Cardiac Stem/Progenitor Cellsfor cardiac repair
Inflammatory (IFN 72h)
Non-Inflammatory
3% O2
low immunogenic profile
IL-10 producing CD4+ cells
Lauden L. et al, Circ Res, 2013
![Page 26: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/26.jpg)
Immunology of Human Cardiac Stem/Progenitor Cellsfor cardiac repair
Down-regulate an ongoing immune response (CD4+, CD8+, IFN, IL-2)
hCPC are Immuno-modulators
Lauden L. et al, Circ Res, 2013
More potent within inflammatory conditions
![Page 27: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/27.jpg)
hCPC & Regulatory T cells
ALLOGENEIC hCPC ACTIVATE AND EXPAND T regs ALLOGENEIC hCPC ACTIVATE AND EXPAND T regs
![Page 28: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/28.jpg)
Characterisation of hCPC activated Regulatory T cells
HLA DR+ PD-1+ Regulatory T CellsHLA DR+ PD-1+ Regulatory T Cells
![Page 29: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/29.jpg)
PD-L1 (1)
anti-PD-L1 anti-PD-L1
Inhibition of Treg expansion
Inhibition of the Immunomodulatory
effect
![Page 30: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/30.jpg)
siRNA Inhibition siRNA Inhibition
PD-L1 (2)
PD-L1 is implicated in Treg s activation & immunomodulation by hCPCsPD-L1 is implicated in Treg s activation & immunomodulation by hCPCs
![Page 31: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/31.jpg)
Conclusions
• hCPC are attractive for clinical Translation- Low immunogenic profile( No immediate rejection ? )-Maintainance of immunologic properties under inflammatory conditions-Immunomodulatory properties
• PD-L1/PD-1 orchestrate immunologic properties of hCPC- Treg generation- hCPC-induced immunomodulation
• Allogenic-driven benefit?- hCPC-induced allogenic response is biased towards Treg- Immune properties of hCPC are controlled by PD-L1/PD-1 pathway
• hCPC are attractive for clinical Translation- Low immunogenic profile( No immediate rejection ? )-Maintainance of immunologic properties under inflammatory conditions-Immunomodulatory properties
• PD-L1/PD-1 orchestrate immunologic properties of hCPC- Treg generation- hCPC-induced immunomodulation
• Allogenic-driven benefit?- hCPC-induced allogenic response is biased towards Treg- Immune properties of hCPC are controlled by PD-L1/PD-1 pathway
![Page 32: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/32.jpg)
ALLOGENICITY
Allogenic-driven-risk versus Allogenic-driven-benefit
Beneficial Detrimental
Optimization of ALLOGENIC STEM CELLS for use in Regenerative Medicine
Immunologically educated choice of ALLOGENIC STEM CELLS
Immune behavior of other stem cells (iPSC and ESC- and iPSC-derived progenitors)
Regulation of MHC expression in stem cells and their progenitors
Reactivity with allo-antibodies (risk or benefit?)
Markers of selection (PD-L1?)
![Page 33: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/33.jpg)
Allogeneic ESCs are Immunogenic : alloimmunity
2010 - 2012
Reprogrammed iPSCs are immunogenic :autoimmunity
Gene Transduced cells are immunogenic: autoimmunity
Allogeneic MSCs are immunogenic:alloimmunity
Endomyocardiac stem cells are allogeneic and Immunomodulatory
Immune CellImmune Cell
Stem CellStem Cell
2002 - 2010
![Page 34: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/34.jpg)
• IMMUNOGENETIC SELECTION/BANK OF SC/MATCHING
• INDUCTION OF TOLERANCE
• IMMUNOMODULATION• IMMUNOMONITORING
![Page 35: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/35.jpg)
Immunogenetic selection– HLA MATCHING - REDUCING HLA MISMATCHING
• Pre TX Screening for anti HLA Characterizing anti HLA specificities(SAB) + MIC-A? C1Q? C4d? Cross-Matching
Post TX monitoring anti HLA antibodies
STEM CELL BANKING Autologous Cells (anticipatory) Cells derived from Homozygous individuals (frequent haplotypes) Allogenic Cells
![Page 36: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/36.jpg)
A transplant immunologist point of view
• Minimize immunogenetic differences
• Assay the immunization status of the recipient prior to SCT injection
• Monitor allogenic & autoimmunity post SCT
• Be pragmatic (…immunosupression) and
• Utopic( …hope for tolerance one day )
![Page 37: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/37.jpg)
AcknowledgementAcknowledgement
Luis BorladoMiguel Mulet ParadaCoretherapix (Madrid, Spain)
Bernardo Nadal-GinardGeorgina EllisonLiverpool John Moores University (Liverpool, UK)
FP7 – CARE-MI Consortium
, INSERM; EU FP7 – CARE-MI
Reem AL DACCAK
Khaoussou Sylla Isabelle Martins Kiran RamgolamLaura LaudenWahid Boukouaci
Hopital Saint-Louis
ICIC
TC&SCTC&SC
UMRS940
Ryad Tamouza
Caroline Suberbielle
Pascale Loiseau Emeline Masson
![Page 38: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/38.jpg)
NOW THIS IS NOT THE ENDIT IS NOT EVEN THE BEGINNING OF THE END
BUT IT IS PERHAPS,
THE END OF THE BEGINNING…THE END OF THE BEGINNING…
Hopital Saint-Louis
HLA IMMUNITY & STEM CELL THERAPY 2013
![Page 39: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/39.jpg)
![Page 40: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/40.jpg)
HLA-class I(850)
HLA-DR(7)
HLA-DQ(0)
HLA-DP(18)
CD40(0)
CD80(0)
CD86(33)
HLA-DR(405)
HLA-DQ
(540)
HLA-DP
(540)
HLA-class I
(18400)
Immune phenotype: HLA expressionImmune phenotype: HLA expressionImmune phenotype: HLA expressionImmune phenotype: HLA expression
hCSC-IFN
MHC II… inductiononly seen when cells are maintained under
hypoxia (3% O2)
physiological inflammatory conditions…?
hCSC
![Page 41: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/41.jpg)
hCPC IMMUNOPHENOTYPE
RESTING & UNDER INFLAMMATORY CONDITION (INF g treated)
No change in morphology & pulripotency markers after IFNγ treatment
Induction of HLA-class IIIncrease expression of HLA-class I & PD-L1
hCPC display a low immunogenic profile
+ INF G
![Page 42: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/42.jpg)
Immunology of Human Cardiac Stem/Progenitor Cellsfor cardiac repair
Low immune risk even within inflammatory environment
Reparatory by promoting Treg and by their expression of PD-L1*Regulatory T cells are implicated in cardiac repair after Myocardial infarction
Tang TT, et al. Cell Physiol Biochem. 2010; Dobaczewski M, et al. Am J Pathol. 2010; Tang TT, et al. Basic Res Cardiol. 2012
*Myocardial PD-L1/PD1 control immune-mediated cardiac injury and polymorphonuclear inflammation Grabie N, et al. Circulation. 2007;116:2062
Allogenic Human Cardiac Progenitor Cells
PD-L1-Dependent Allogenic-Driven Benefit
PromotesClinical Translation
Highlights PD-L1
marker Identify & Select
Low-Risk/High-Benefit allogenic cardiac repair cells
NK cells response Reactivity with anti-HLA antibodies
![Page 43: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/43.jpg)
CD4+ T cells
hCSCs-triggered Allogenic Response
![Page 44: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/44.jpg)
PHA alone Allo PBMC CSCs
CSCs + IFNγ MSCs
CD
4C
D8
89.1% 95.3% 71.6% 70.4% 28.1%
90.7% 97.1% 71.6% 19.6%69.6%
T c
ell
pro
life
rati
on
CFSE
hCSCs immune-modulation of an ongoing T cell response
![Page 45: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/45.jpg)
CSCs
PBMC
CSCs can be recognized by anti HLA allo-antibodies
![Page 46: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/46.jpg)
SUMMARYSUMMARYSUMMARYSUMMARY
CSCs express MHC I and MHC II under physiological & inflammatory situation
They display higher ALLOGENICITY than MSCs and are less powerful in down regulating an ongoing immune response
CSC capacity to induce or modulate an immune response is variable depending on both donor and recipient
CSCs are recognized by allo-anti-HLA sera, which can
lead to in their elimination but could also be part of their paracrine effect
Circulation Research 2012(in press)
![Page 47: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/47.jpg)
![Page 48: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/48.jpg)
Immunosuppressive Therapy Mitigates Immunological Rejection of Human Embryonic Stem Cell XenograftsR.J SWIJNENBURG, S. SCHREPFER, J.A. GOVAERT, F. CAO, K. RANSOHOFF, A.Y SHEIKH, M. HADDAD, A.J CONNOLLY, M.M DAVIS, R.C ROBBINS, J.C WU
PNAS, 2008,105:12991
IN VIVO VISUALIZATION OF HESC SURVIVAL
Immune CellImmune Cell
Stem CellStem Cell
![Page 49: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/49.jpg)
hCPC induced T Cell Response
Allogeneic co culture: CFSE Labelled PBMC/ Mitomycin-C treated hCPC Allogeneic co culture: CFSE Labelled PBMC/ Mitomycin-C treated hCPC
Low response similar to MSC induced Low IFNγ & IL-2 productionHigh IL10 Production
hCPC induce low allogeneic T-cell responsehCPC induce low allogeneic T-cell response
![Page 50: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/50.jpg)
Oct4
Sox2
Nanog
-actin
PBM
Cs
CSC-
IFNγ
CSC
MSC
DAPI NKx2.5
DAPI oct4
DAPI SSEA-
4
DAPI FITC-
IgG
DAPI PE-IgG
DAPI FITC-IgG
Cel
l co
un
ts
Fluorescence intensity
c-kit(48)
CD90(2880)
SSEA-1(269)
SSEA-4(1779)
CD166(100)
CD44(14955)
Human cardiac Stem Cells characterization
Cells from three different donors
CH1, CH3, CH4
Cardiac differenciation potency
(In vitro)
Cardiomyocyte
Endothelial
Smooth muscle
Endomyocardic BiopsyCollagenase treatementC-kit purification/enrichment
Nadal-Ginard B et al. Resident human cardiac stem cells: role in cardiac cellular homeostasis and potential for myocardial regeneration. Nat Clin Pract Cardiovasc Med 2006;3
2012
![Page 51: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/51.jpg)
Immunology of Human Cardiac Stem/Progenitor Cellsfor cardiac repair
Lauden L. et al, Circ Res, 2013
hCPC in allogenic settings have the ability to induce tolerance, by promoting allo-stimulation and a contact and PD-L1-dependent
regulatory response
HLA-DR+ PD1+ Regulatory T cells
![Page 52: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/52.jpg)
2011
• INDUCED PLURIPOTENT STEM CELLS(iPS) ARE IMMUNOGENIC & RESULT IN AUTO-IMMUNITY
IN THE NEWS
![Page 53: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/53.jpg)
Immunogenicity of induced pluripotent stem cellsT. Zhao, Z-N Zhang, Z. Rong and Y. Xu
Nature, 2011, doi:10.1038/nature10135
Immune CellImmune Cell
Stem CellStem Cell
ESCs from C57BL/6
ESCs from 129/SvJ
B6
B6
Teratomal Immune Rejection/Tumor Regression
(IR/TR)0
+++
* Proof of Principle
IR/TR
* Reprogramming of of B6 Embryonic Fibroblast (MEF)Oct4,Sox2,Klf4/Oct4,Sox2,Myc, Klf4
Retroviral Approach
ViPSCs Episomal Approach
EiPSCs
B6 mice+++ ++ CD4 T cell infiltration/Cell necrosis
![Page 54: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/54.jpg)
Mechanisms??Mechanisms??* Gene profiling of EiPSCs
Major findings* episomal vector is deleted* abnormal overexpression of endogenous genes
- Hormad 1 (tumor specific Ag)- Spt1 (tumor specific Ag)- Zg16
* Immune Rejection/Tumor Rejection
Major findings* CD4 CD8 mediated immune rejection through Ag specific (Zg16, Hormad1) T cells
- confirmed by in vivo purified T cells (Ag specific) detected by (IFN release
assay) upon co-culture with Ag-transfected DC from B6 mice
ConclusionConclusion
Break of Peripheral Tolerance/Expression of Minor AntigensBreak of Peripheral Tolerance/Expression of Minor AntigensImmune CellImmune Cell
Stem CellStem Cell
![Page 55: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/55.jpg)
Clinical translation can only be successful if good knowledge of biological processes linked to the therapeutic effect exists
Cancer Stem Cells Stem Cells
Factors promoting their Immune Behavior
PluripotencySelf-renewal
PlasticityImmune-modulation
Common Distinct
How these cells are Tolerated to persist
EngraftmentRepair
EliminateCombat
BiomarkersImmune protocols
Targets
(PD-L1?, MHC II?)
![Page 56: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/56.jpg)
hCPC Immunomodulatory property
hCPC are capable to modulate an ongoing Immune response hCPC are capable to modulate an ongoing Immune response
PHA polyclonal stimulation PHA polyclonal stimulation
![Page 57: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/57.jpg)
the function of MHC II molecules is not limited to their role as antigen-presenting structures; they are receptors that by triggering a variety of signaling pathways can regulate cells activities from proliferation and maturation to apoptosis
Could a signal via MHC II or I contribute to the Regenerative PARACRINE effect of allogenic CSCs???
![Page 58: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/58.jpg)
SUMMARYSUMMARYSUMMARYSUMMARY
CSCs express MHC I and MHC II under physiological & inflammatory situation
They display higher ALLOGENICITY than MSCs and are less powerful in down regulating an ongoing immune response
CSC capacity to induce or modulate an immune response is variable depending on both donor and recipient
CSCs are recognized by allo-anti-HLA sera, which can
lead to in their elimination but could also be part of their paracrine effect
Circulation Research 2012(in press)
![Page 59: Allogeneicity and Immunogenicity of Stem Cell Therapy : a cardiovascular focus](https://reader035.fdocuments.in/reader035/viewer/2022062418/556ef72bd8b42ad36d8b5147/html5/thumbnails/59.jpg)
Additional Challenges
• Injured myocardium is inflammatory:Immune reactivity increase
• Presence of APC within the differenciated cell population(Endothelial ,Dentritic cells …)
• MHC class I expression :NK cells susceptibility vs Cytotoxic T lymphocytes